title: Admission hyperglycemia in patients with acute coronary syndrome complicated by cardiogenic shock.
abstract: BACKGROUND
  Many reports shoed that for patients with acute coronary syndrome (ACS) increased admission blood glucose (ABG) level is associated with adverse outcomes. Although scientific reports on this issue are still inconsistent, many recent studies confirm that hyperglycemia is also an unfavorable prognostic factor in patients with ACS complicated by cardiogenic shock (CS). The aim of this study is to determine if hyperglycemia on admission can be a predictor of in-hospital death in patients with ACS complicated by CS.
  
  
  METHODS
  The study population consisted of 40 patients with ACS complicated by CS admitted to the Intensive Cardiac Therapy Clinic from January 2010 to May 2013 and treated with primary percutaneous coronary intervention. A control group was selected among patients with uncomplicated ACS.
  
  
  RESULTS
  Patients with CS had significantly higher levels of ABG (15.4 ± 6.26 vs. 7.97 ± ± 2.28 mmol/L, p < 0.01) in comparison with the control group. There was no statistically significant correlation between the level of glucose on admission and in-hospital mortality. Average ABG in patients who survived and in those who died were respectively 15.42 ± 5.61 vs. 15.40 ± 6.87 mmol/L, p > 0.05. Comparison in groups depending on ABG level and calculations with use of receiver-operating characteristics curves showed no relationship between the level of ABG and patients' deaths.
  
  
  CONCLUSIONS
  Hyperglycemia on admission is a clinical feature of patients with ACS who develop CS, however its prognostic value requires further studies.
authors.affiliation: Intensive Cardiac Therapy Clinic, Medical University of Lodz Łódź. cparamedikus@gmail.com.
authors.forename: Filip
authors.initials: F
authors.lastname: Jaśkiewicz
authors.forename: Karolina
authors.initials: K
authors.lastname: Supeł
authors.forename: Włodzimierz
authors.initials: W
authors.lastname: Koniarek
authors.forename: Marzenna
authors.initials: M
authors.lastname: Zielińska
mesh_terms: D054058:Acute Coronary Syndrome / Q000150:complications* / Q000175:diagnosis / Q000401:mortality / Q000628:therapy; D000368:Aged; D000369:Aged, 80 and over; D019540:Area Under Curve; D015415:Biomarkers / Q000097:blood; D001786:Blood Glucose / Q000032:analysis*; D016022:Case-Control Studies; D005260:Female; D017052:Hospital Mortality; D006801:Humans; D006943:Hyperglycemia / Q000097:blood / Q000150:complications* / Q000175:diagnosis / Q000401:mortality; D008297:Male; D008875:Middle Aged; D010343:Patient Admission; D062645:Percutaneous Coronary Intervention; D011237:Predictive Value of Tests; D011446:Prospective Studies; D012372:ROC Curve; D012042:Registries; D018570:Risk Assessment; D012307:Risk Factors; D012770:Shock, Cardiogenic / Q000175:diagnosis / Q000209:etiology* / Q000401:mortality / Q000628:therapy; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D001786:Blood Glucose